Incorporating technology in smoking cessation interventions: In-person vs. Video-call formats.

Int J Med Inform

Smoking and Addictive Disorders Unit, Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain; Institute of Research in Psychology (IPsiUS), University of Santiago de Compostela (USC), Santiago de Compostela, Spain.

Published: December 2024

Introduction: The use of video calls to provide health-related interventions has grown significantly, showing positive results in a broad range of psychological interventions. Scarce research has examined video-call use in smoking cessation treatments. The purpose of this study was to compare two randomised controlled trials conducting a cognitive-behavioral intervention to quit smoking in-person versus using video calls.

Material And Methods: This study is a secondary analysis of two randomised controlled trial studies (RCTs) conducted using two delivery formats: in-person vs. video calls. The sample comprised 498 adults seeking smoking cessation treatment. We analysed smoking cessation, cigarette reduction, and treatment satisfaction outcomes according to delivery format.

Results: No significant differences were found in sex, age, and baseline smoking-related variables. A significantly higher proportion of participants in the video-call format had university studies, were actively working, and had a history of depression compared to the in-person format. No significant differences were found in cessation, smoking reduction, and satisfaction with treatment. Predictive variables of 12-month abstinence were: baseline number of cigarettes smoked per day (OR = 0.93) in the case of the in-person format; and being a woman (OR = 0.53), cigarette dependence (OR = 0.46), and last year quit attempt (OR = 0.52) in the video-call format.

Conclusions: Both delivery formats showed similar abstinence rates at 12 months and satisfaction with the intervention. Therefore, in-person and video calls could be used to deliver smoking cessation treatments. Given that predictors of long-term abstinence differed across these delivery formats, further research is needed.

Trials Registration: ClinicalTrials.gov IDs: NCT02844595: NCT04765813.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijmedinf.2024.105774DOI Listing

Publication Analysis

Top Keywords

smoking cessation
20
video calls
12
delivery formats
12
cessation treatments
8
randomised controlled
8
in-person video
8
in-person format
8
smoking
7
cessation
6
in-person
6

Similar Publications

Trends in the Prevalence of Korean Adolescent Smokers According to Smoking Cessation Policy and COVID-19.

Asia Pac J Public Health

January 2025

Department of Dental Hygiene, College of Software and Digital Healthcare Convergence, Yonsei University, Wonju, South Korea.

This study evaluates the influence of smoking cessation policies and COVID-19 on the prevalence of smoking among Korean adolescents from 2011 to 2020. Based on the Korea Youth Risk Behavior Web-based Survey, trends in adolescent smoking behaviors were examined, including the impact of cigarette price increases, Pictorial Warning Labels (PWLs), and the onset of COVID-19. We used joinpoint regression analysis to discern annual changes in the prevalence of adolescent smokers.

View Article and Find Full Text PDF

Background: Smoking rates in the UK have declined steadily over the past decades, masking considerable inequalities, as little change has been observed among people with a mental health condition. This trial sought to assess the feasibility and acceptability of supplying an electronic cigarette (e-cigarette) starter kit for smoking cessation as an adjunct to usual care for smoking cessation, to smokers with a mental health condition treated in the community, to inform a future effectiveness trial.

Methods: This randomised controlled feasibility trial, conducted March-December 2022, compared the intervention (e-cigarette starter kit with a corresponding information leaflet and demonstration with Very Brief Advice) with a 'usual care' control at 1-month follow-up.

View Article and Find Full Text PDF

The smoking cessation drug cytisine exerts neuroprotection in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons of female but not male 6-hydroxydopamine (6-OHDA) lesioned parkinsonian mice. To address the important question of whether circulating 17β-estradiol mediates this effect, we employ two mouse models aimed at depleting systemically circulating 17β-estradiol: (i) bilateral ovariectomy (OVX), and (ii) aromatase inhibition with systemically administered letrozole. In both models, depleting systemically circulating 17β-estradiol in female 6-OHDA lesioned parkinsonian mice results in the loss of cytisine-mediated neuroprotection as measured using apomorphine-induced contralateral rotations and SNc DA neurodegeneration.

View Article and Find Full Text PDF

In 2024, Philip Morris International's (PMI) website stated they support 'independent' continuing medical education courses on harm reduction for medical and other healthcare professionals. These courses mirrored industry marketing and political strategies by presenting smokeless tobacco products and e-cigarettes as alternatives to smoking, sometimes without mentioning tobacco cessation. The enactment of the US Family Smoking and Tobacco Control Act gave the US Food and Drug Agency jurisdiction over tobacco products and included the industry's 'continuum of risk' frame, and emboldened tobacco companies to make harm reduction claims about these products, which they had previously avoided for fear of triggering restrictive regulation of cigarettes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!